Personalized Neoantigen-Based Cancer Therapy and Prevention Platform

A next-generation cancer treatment and prevention platform integrating tucaresol or analog-based compounds with advanced technologies such as machine learning, gene editing, and synthetic adjuvants to provide personalized, targeted, and effective immune responses against cancer.

The original patent disclosed compositions containing tucaresol or its analogs for cancer treatment, but it had limitations in terms of specificity, efficacy, and patient variability. The new inventive concept addresses these limitations by envisioning a comprehensive platform that combines tucaresol or analog-based compounds with cutting-edge technologies to provide a tailored approach to cancer therapy and prevention.

The platform consists of multiple components: a tucaresol or analog-based compound, a machine learning module for predicting patient-specific tumor mutations, a nanoparticle delivery system for targeted immune activation, a gene editing tool for enhancing tumor-specific immune responses, a synthetic adjuvant for enhancing immune cell activation and tumor infiltration, a point-of-care cancer diagnosis device, and a wearable device for monitoring immune system function. These components work together to provide a personalized, adaptive, and effective approach to cancer treatment and prevention.

The new claims introduce a paradigm shift in cancer therapy and prevention by integrating tucaresol or analog-based compounds with advanced technologies, providing a holistic and patient-centric approach that is not obvious from the original patent. The inventive concept's novelty lies in the synergistic combination of these components, which enables a more targeted, effective, and personalized approach to cancer treatment and prevention.

Alternative embodiments of the platform could include different machine learning algorithms, various gene editing tools, or diverse synthetic adjuvants. Additionally, the platform could be adapted for different types of cancer, or integrated with other therapeutic modalities such as radiation or surgery.

The personalized neoantigen-based cancer therapy and prevention platform has significant commercial potential in the oncology market, with potential applications in cancer treatment, prevention, and diagnosis. The target industries include pharmaceutical companies, biotech firms, and healthcare providers.